Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure

• US 8,016,783 B2
• Filed: 12/03/2007
• Issued: 09/13/2011
• Est. Priority Date: 08/21/2003
• Status: Active Grant

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Reeve, Helen L., Ross, Jeffrey, Spinelli, Julio C., Pastore, Joseph M., Salo, Rodney W., Shuros, Allan
• Primary Examiner(s): Lucchesi; Nicholas D
• Assistant Examiner(s): FLICK, JASON E
• Application Number:
  US11/998,969
• Publication Number:
  US 20080091138A1
• Time in Patent Office: 1,380 Days
• Field of Search: 604/67
• US Class Current: 604/67
• CPC Class Codes: A61B 5/0031 Implanted circuitry
• CPC Class Codes: A61B 5/1107 Measuring contraction of parts of the body, e.g. organ, muscle apparatus for measuring work or force in general G01L
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/4839 combined with drug delivery
• CPC Class Codes: A61M 2205/3523 using telemetric means
• CPC Class Codes: A61M 5/14244 adapted to be carried by the patient, e.g. portable on the body
• CPC Class Codes: A61M 5/14276 specially adapted for implantation
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: A61N 1/3627 for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy

Abstract

A drug delivery system detects a cardiac condition indicative of a need for increasing a cardiac metabolic level and, in response, releases a drug into tissue or blood to shift a source of metabolically synthesized energy fueling cardiac contraction from fatty acid to glucose. One example of such a system includes an implantable device detecting an ischemia and a transdermal drug delivery device delivering a drug when an ischemic condition is detected. Another example of such a system includes one or more implantable devices detecting a predefined change in cardiac metabolic level and delivering a drug when the change is detected. Such systems are applied to treat, for example, patients suffering ischemia and/or heart failure and patients having suffered myocardial infarction.

Claims

1. A system, comprising:

a transdermal drug delivery device adapted to deliver a drug;

an implantable cardiac rhythm management (CRM) device communicatively coupled to the transdermal drug delivery device, the implantable CRM device including;

an ischemia detector adapted to detect an ischemia and produce an ischemia indicating signal in response to a detection of the ischemia;

a drug level detector including a respiratory sensor adapted to sense a respiratory signal as an indication of whether a blood drug concentration is below a predetermined minimum level after a delivery of the drug; and

a drug delivery controller coupled to the ischemia detector and the drug level detector; and

an external device communicatively coupled to the implantable CRM device, the external device including an external user input to receive an external user command,

wherein the drug delivery controller is adapted to control the transdermal drug delivery device based on at least one of the ischemia indicating signal, the indication of the blood drug concentration, and the external user command.

2. The system of claim 1, wherein the implantable CRM device comprises a sensing circuit to sense at least one electrogram.

3. The system of claim 2, wherein the ischemia detector comprises an input coupled to the sensing circuit and an ischemia analyzer to produce the ischemia indicating signal based on an analysis of the at least one electrogram.

4. The system of claim 1, wherein the ischemia detector comprises:

an impedance sensor to sense an electrical impedance signal; and

an ischemia analyzer to produce the ischemia indicating signal based on an analysis of the electrical impedance signal.

5. The system of claim 1, wherein the ischemia detector comprises:

an accelerometer to sense an acceleration signal; and

an ischemia analyzer to produce the ischemia indicating signal based on an analysis of the acceleration signal.

6. The system of claim 1, further comprising:

a remote device receiving signals including at least one of the external user command and the at least one electrogram; and

a network coupled between the external device and the remote device to provide for bidirectional communication between the external device and the remote device.

7. The system of claim 6, wherein the remote device comprises an emergency response module adapted to contact an emergency response unit in response to the external user command.

8. The system of claim 6, wherein the remote device comprises a remote signal processor to process the received signals using at least one predetermined algorithm.

9. The system of claim 8, wherein the remote device further comprises a remote user interface providing for monitoring of the processed received signals and entry of remote user commands.

10. The system of claim 9, wherein the remote device further comprises a remote device controller adapted to generate commands controlling one or more of the transdermal drug delivery device, the implantable CRM device, and the external device based on the received signals and the remote user commands.

11. The system of claim 1, wherein the transdermal drug delivery device comprises a drug reservoir containing one or more pharmaceutical agents shifting a source of metabolically synthesized energy for cardiac contractions from fatty acid to glucose.

12. The system of claim 11, wherein the transdermal drug delivery device further comprises at least one skin contact electrode for transdermal drug delivery.

13. The system of claim 11, wherein the one or more pharmaceutical agents comprise one or more of agents decreasing, inhibiting, and/or reducing fatty acid oxidation and agents increasing, enhancing, and/or stimulating pyruvate, glucose, and/or lactate oxidation.

14. The system of claim 13, wherein the one or more pharmaceutical agents further comprise one or more of anti-hypertensive agents, anti-arrhythmic agents, pressors, vasopressors, vasodilators, anti-hyperlipidemic agents, anti-anginal agents, ionotropic agents, diuretics, volume expanders, thrombolytics, anti-platelet agents, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, and angiotensin receptor blockers.

15. The system of claim 11, wherein the transdermal drug delivery device further comprises a drug delivery status indicator adapted to allow monitoring of whether the one or more pharmaceutical agents are being delivered.

16. The system of claim 11, wherein the transdermal drug delivery device further comprises a drug delivery status indicator adapted to allow monitoring of an amount of the one or more pharmaceutical agents remaining in the drug reservoir.

17. The system of claim 1, wherein the transdermal drug delivery device is configured to be a skin patch.

18. The system of claim 17, wherein the skin patch allows for electrically controlled transdermal drug delivery by iontophoresis, electroporation, electrorepulsion, or electro-osmosis.

19. The system of claim 1, wherein the external user input comprises a push button.

20. The system of claim 1, wherein the external user input comprises a voice controlled switch.